141 related articles for article (PubMed ID: 18470756)
1. Sample size calculations in thorough QT studies.
Zhang L; Dmitrienko A; Luta G
J Biopharm Stat; 2008; 18(3):468-82. PubMed ID: 18470756
[TBL] [Abstract][Full Text] [Related]
2. Statistical issues including design and sample size calculation in thorough QT/QTc studies.
Zhang J; Machado SG
J Biopharm Stat; 2008; 18(3):451-67. PubMed ID: 18470755
[TBL] [Abstract][Full Text] [Related]
3. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ
Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
[TBL] [Abstract][Full Text] [Related]
4. On power and sample size calculation for QT studies with recording replicates at given time point.
Chow SC; Cheng B; Cosmatos D
J Biopharm Stat; 2008; 18(3):483-93. PubMed ID: 18470757
[TBL] [Abstract][Full Text] [Related]
5. Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables.
Cheng B; Chow SC; Burt D; Cosmatos D
J Biopharm Stat; 2008; 18(3):494-501. PubMed ID: 18470758
[TBL] [Abstract][Full Text] [Related]
6. QT/QTc prolongation in placebo-treated subjects: a PhRMA collaborative data analysis.
Agin MA; Aronstein WS; Ferber G; Geraldes MC; Locke C; Sager P
J Biopharm Stat; 2008; 18(3):408-26. PubMed ID: 18470753
[TBL] [Abstract][Full Text] [Related]
7. Statistical analysis methods for QT/QTc prolongation.
Ma H; Smith B; Dmitrienko A
J Biopharm Stat; 2008; 18(3):553-63. PubMed ID: 18470763
[TBL] [Abstract][Full Text] [Related]
8. Effect of baseline measurement on the change from baseline in QTc intervals.
Tian H; Natarajan J
J Biopharm Stat; 2008; 18(3):542-52. PubMed ID: 18470762
[TBL] [Abstract][Full Text] [Related]
9. Statistical issues of QT prolongation assessment based on linear concentration modeling.
Tsong Y; Shen M; Zhong J; Zhang J
J Biopharm Stat; 2008; 18(3):564-84. PubMed ID: 18470764
[TBL] [Abstract][Full Text] [Related]
10. Testing for positive control activity in a thorough QTc study.
Zhang J
J Biopharm Stat; 2008; 18(3):517-28. PubMed ID: 18470760
[TBL] [Abstract][Full Text] [Related]
11. A statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QT studies.
Stylianou A; Roger J; Stephens K
J Biopharm Stat; 2008; 18(3):502-16. PubMed ID: 18470759
[TBL] [Abstract][Full Text] [Related]
12. Guest editors' notes on statistical issues in design and analysis of thorough QTc studies.
Tsong Y; Zhang J
J Biopharm Stat; 2008; 18(3):405-7. PubMed ID: 18470752
[No Abstract] [Full Text] [Related]
13. Sample size calculation for thorough QT/QTc study considering various factors related to multiple time points.
Meng Z; Kringle R; Chen X; Zhao PL
J Biopharm Stat; 2010 May; 20(3):563-77. PubMed ID: 20358436
[TBL] [Abstract][Full Text] [Related]
14. Effect of number of replicate electrocardiograms recorded at each time point in a thorough QT study on sample size and study cost.
Natekar M; Hingorani P; Gupta P; Karnad DR; Kothari S; de Vries M; Zumbrunnen T; Narula D
J Clin Pharmacol; 2011 Jun; 51(6):908-14. PubMed ID: 20852005
[TBL] [Abstract][Full Text] [Related]
15. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
[TBL] [Abstract][Full Text] [Related]
16. Validation testing in thorough QT/QTc clinical trials.
Tsong Y; Zhong J; Chen WJ
J Biopharm Stat; 2008; 18(3):529-41. PubMed ID: 18470761
[TBL] [Abstract][Full Text] [Related]
17. Comparison of six commonly used QT correction models and their parameter estimation methods.
Wang D; Taubel J; Arezina R
J Biopharm Stat; 2012; 22(6):1148-61. PubMed ID: 23075014
[TBL] [Abstract][Full Text] [Related]
18. Bias and variance evaluation of QT interval correction methods.
Wang Y; Pan G; Balch A
J Biopharm Stat; 2008; 18(3):427-50. PubMed ID: 18470754
[TBL] [Abstract][Full Text] [Related]
19. The joint modeling of drug and positive control effects to estimate sample size and power in crossover "thorough" QT/QTc studies.
Hosmane B; Locke C; Chiu YL
J Biopharm Stat; 2013; 23(4):871-80. PubMed ID: 23786591
[TBL] [Abstract][Full Text] [Related]
20. Impact of baseline ECG collection on the planning, analysis and interpretation of 'thorough' QT trials.
Sethuraman V; Sun Q
Pharm Stat; 2009; 8(2):113-24. PubMed ID: 18481273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
